ACR/ARHP 2018 Annual Meeting
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
ACR/ARHP 2018 Annual Meeting
Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.
ACR/ARHP 2018 Annual Meeting
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."
ACR/ARHP 2018 Annual Meeting
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
ACR/ARHP 2018 Annual Meeting
Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.
ACR/ARHP 2018 Annual Meeting
Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.
ACR/ARHP 2018 Annual Meeting
A diagnosis of cardiovascular disease or presence of related biomarkers, as well as the use of antirheumatic drugs may be associated with a higher risk for heart failure in patients with rheumatoid arthritis.